



**DISCOVERY**  
L I F E   S C I E N C E S

Science at your Service™

# AllCells® GMP Product Catalog

*Primary Human Cells and Tissues*



## The Patient, their Hope, and our **Commitment.**

Hope enables the patient to endure the adversity and pain of disease. Hope motivates people to participate in clinical research studies and biospecimen donation. Time is the worst enemy of hope. As time passes, it prolongs and intensifies pain while diminishing the body and spirit.

Our mission is to enable the discovery and development of therapeutic and diagnostic solutions that improve patient outcomes.

At Discovery Life Sciences, we commit to acquiring the leading technologies and employing the most dedicated and brightest minds from every culture, walk of life, and region of the world. We come together to accelerate and advance science. We accomplish this by partnering with researchers in industry, academia, and governments enhancing their abilities to complete their vital work faster by providing them with the highest quality products and services. We commit to acting ethically and with integrity while strictly adhering to all laws and regulations.

We will never waiver from these commitments...

*Because Patients Are Waiting<sup>®</sup>.*



# TABLE OF CONTENTS

Science at your Service™	4
High Quality Starting Cellular Material to Support GMP Manufacturing	6
AllCells® GMP Fresh Leukopak	8
AllCells® GMP Cryopreserved Leukopak	10
GMP Cleanroom	12
Pre-Characterized Donor Selection Program	14
AllCells® GMP Mobilized Leukopak	16
AllCells® GMP Bone Marrow	18
AllCells® GMP Cryopreserved PBMCs	19
Continuum of CGT	20
Donor Qualification for GMP Products	21
Donor Management	22

## Science at your Service™

Discovery combines the world's largest commercial biospecimen inventory and procurement network with preeminent multi-omic service laboratories.

Our consultative, innovative approach helps our customers and partners overcome obstacles to reach quality results faster.





# AllCells®

High Quality RUO and GMP Human Primary Cells

*Serving the complete cell and gene therapy continuum*

**RUO/GMP Mobilized and Non-Mobilized Leukopaks, Isolated Cells, Thousands of Recallable/HLA-Typed Donors**

**Genomics**  
WES, RNA-Seq, Single-Cell, Targeted-Seq, Pan-Cancer, WGS, HiFi LRS, Epigenomics, qPCR

**Proteomics**  
Targeted & Untargeted LC-MS/MS, Luminex, Olink (Explore HT, Explore, Target, Focus, Flex), Multi-omics

**Assay-Ready Biospecimens**  
The World's Largest Biospecimen Inventory Powered by Discovery Partners® Network

**Molecular Pathology**  
IHC, mIF, ISH, Histology, Digital Pathology, Quantitative Gene Expression

**Gentest® In Vitro Preclinical**  
Hepatocytes, HLM, Supersomes™, TransportoCells™, ADMET Services, Hematopoietic CFC Assay Services

**Flow Cytometry & Cell Biology**  
Clinical Flow Cytometry, FACS, Dissociations, Single Cell & Spatial Library Prep, In Vitro Culture

# High Quality Starting Cellular Material to Support GMP Manufacturing

Sourcing high-quality cellular material is one of the biggest industry challenges for the development of cell and gene therapies. Discovery's AllCells® products and services support the full continuum of cell and gene therapy (CGT) production - from basic discovery through commercialization and across various modality types. Operating the largest and most diverse repository of healthy, recallable donors, Discovery is well-suited to fulfill a variety of donor attributes.

## **UNPARALLELED ABILITY TO DELIVER**

### **Extensive and Loyal Client Base**


- 400+ unique clients in the past year
- Global reach with fresh and cryopreserved shipments to domestic and international countries

### **Deliverability Rate of 99%**

- 600+ products provided in support of process qualification and GMP manufacturing for cell therapy developers
- Highly communicative and collaborative team with < 24 hour response time
- Dedicated donor facing brand and operations for effective donor recruitment and management
- Characterized donor and inventory ecosystem to support streamlined donor screening and selection
- Built-in risk mitigation measures, including parallel donor screening



Discovery is continuously at the forefront of CGT market requirements, providing the highest quality products and services.





## AllCells® GMP Fresh Leukopak

*A leukopak is an enriched leukapheresis product collected from normal peripheral blood, which contains a concentrated fraction of mononuclear cells like lymphocytes and monocytes.*

Leukopaks are ideal for cell and gene therapy applications requiring lymphocyte populations (i.e., T cells, NK cells) (Fig 1).

AllCells® GMP leukopak products are collected from qualified, healthy, and consenting donors per IRB-approved protocols by our team of experienced clinicians and processed in our FDA-registered facilities. Stringent quality systems ensure regulatory compliance requirements are met. All our GMP products are subjected to an extensive quality review and are provided with supporting extended documentation during batch release.



GMP Fresh Leukopaks are collected from healthy human donors using the Spectra Optia® Apheresis System directly into ACD-A anticoagulant.

GMP Leukopak products are quality controlled for: volume, viability, total nucleated cell (TNC) concentration, and sterility USP <71>. The product is shipped using a validated shipping container.

Catalog Number: CG, LP, FR, Full Pak

**SPECIFICATIONS**

- Anti-coagulant: ACD-A
- Volume: ≥280mL
- Viability: ≥90%
- TNC Concentration: ≥26x10<sup>6</sup> cells/mL
- Sterility test USP <71>: No growth
- Shipping: 2 to 8°C in validated shipping container with temperature logger
- Documentation: Certificate of Analysis (CoA) and Summary of Records (SoR)




Fig 1: Cell Subpopulations in Fresh Leukopak (Donor Variability is Expected)

# AllCells® GMP Cryopreserved Leukopak

*Cryopreserved leukopaks demonstrate comparability to fresh leukopaks*

Discovery's optimized cryopreservation protocols deliver high cell viability of important lymphocyte populations with low-granulocyte contamination.

*Catalog Number: CG, LP, CR, Solo 2.5-3.0B*

## SPECIFICATIONS

- Anti-coagulant: ACD-A
- Format: Full donor collection processed and split into a minimum of 3x CS250 bags per lot with up to 8 retention vials
- Pre-cryopreservation TNC count per bag:  $\geq 2.5$  billion cells
- Cryopreservation media: CS10
- Pre-cryopreservation viability %:  $\geq 90$
- Sterility test USP <71>: No growth
- Shipping:  $< -150^{\circ}\text{C}$  in a validated shipping container with temperature logger
- Documentation: CoA, SoR, Immunophenotyping Report, and CBC 5-Part Differential Report

## CASSETTE AND FRAME

Item	Details
Cassette	ZC021
Cassette Dimension (HxWxD)	6.0" x 7.55" x 0.44"
Cassette Frame	ZF4-ZC021
Cassette Frame Dimension (HxWxD)	25.69" x 6.38" x 0.56"





GMP Cryopreserved Leukopaks tested at two different sampling timepoints (<1 week and 12-months) maintained high cell viability (Fig 2a), yield (Fig 2b), and demonstrated comparable cell subpopulation distribution (Fig 2c).




Fig 2a: Average % Viability Pre-Freeze vs. Post-Thaw




Fig 2b: Average Viable Cell Count Pre-Freeze vs. Post-Thaw




Fig 2c: Average Distribution of Immune Cell Subpopulations



# GMP Cleanroom

All cryopreservation steps performed in our Alameda California facility occur within the ISO 7 cleanroom with grade A and B zones according to Master Batch Record.

- Robust environmental monitoring
- Adjacently located to our collection facility
- One-way product flow
- Cryogenic storage with continuous temperature monitoring and alarming
- Dedicated controlled environment room operations, equipment management, and staff training










# Pre-Characterized Donor Selection Program

## *Characterized Starting Materials*

Donor attributes including age, BMI, race, gender, health history, and viral testing per 21 CFR 1271 regulations along with HLA typing and KIR profiling are compiled for donors eligible for GMP product collections. We also perform a 9-color flow panel immunophenotyping analysis to provide additional characterization data on different immune cell subsets.

- Visualize the real-time status of donors and characterization data
- Streamline and accelerate donor selection process




## Optimized Donor Selection

Our dedicated team helps clients utilize the donor characterization datasets to select the most suitable donors with the attributes that align with their program-specific requirements, and coordinate scheduling of these donors for collections of fresh or cryopreserved leukopak products. This high-resolution data also provides valuable insights about how starting material attributes influence the final CGT product, which helps researchers and process engineers develop more robust and controlled manufacturing processes to ensure consistency and quality throughout the entire production workflow.

## Streamlined Workflow

Our streamlined approach significantly reduces the timeline compared to conventional workflows, where it is necessary to recall donors for whole blood screening\* and characterization, prolonging the donor selection process.



\* Whole blood screening options are available for custom donor attributes not included in inventory



## AllCells® GMP Mobilized Leukopak

*GMP Mobilized Leukopaks are collected from healthy, human donors using the Spectra Optia Apheresis System after the donors have been treated with FDA-approved drugs, filgrastim and plerixafor, to stimulate mobilization of CD34+ hematopoietic stem and progenitor cells from the bone marrow to the peripheral blood.*

GMP Mobilized Leukopak products are quality controlled for: volume, viability, and sterility USP <71>. The product is shipped using a validated shipping container. Available in fresh format only.

In normal, non-mobilized peripheral blood, the frequency of CD34+ cells is extremely low, at only 0.01– 0.05%. Mobilization of HSPCs from the bone marrow to the peripheral blood using FDA-approved drugs is an effective mechanism to boost CD34+ frequency prior to leukapheresis collection. On average, the CD34+ cell count from a dual mobilization is more than 180 times that of a single bone marrow collection.



## VIABILITY AND CELL COUNT

Average TNC count (10 <sup>6</sup> ) per donor	Average % Viability	Average % CD34+ Cells (ISHAGE)
127,792	97.0%	1.25%


Catalog Number: CG, mLP, RegH, FR, Full Pak / CG, mLP, RegH, FR, Full Pak 2


### SPECIFICATIONS

- Mobilized Regimen: Filgrastim x 5 days, + Plerixafor x 2 days (RegH)
- Format: Fresh, 2 Paks
- Anticoagulant: ACD-A
- Fill Volume: ≥ 280mL per bag
- Viability: ≥ 90%
- Sterility Test USP <71>: No growth
- Shipping Condition: 2 to 8°C in validated shipping container with temperature logger
- Documentation: CoA and SoR
- International Society of Hematotherapy and Graft Engineering
- (ISHAGE) report and CBC 5-Part Differential report are available upon request

### REGIMEN DETAILS

- Filgrastim 10µg/kg/day x 5 days + Plerixafor 240µg/kg/day x 2 days on day 4 and 5 (evenings)
- Apheresis on day 5 and 6





## AllCells® GMP Bone Marrow

*Bone Marrow aspirate products are a rich source of CD34+ cells, mesenchymal stem cells (MSCs), and other leukocytes.*

GMP Bone Marrow is collected from healthy, human donors by needle aspiration from the posterior iliac crest. GMP bone marrow products are quality controlled for: volume, viability, TNC concentration, and sterility USP <71>. Available in fresh format only.

**Catalog Number:** CG, BM, FR, 1ea (100mL)

### SPECIFICATIONS

- Anti-coagulant: Na Heparin or ACD-A
- Volume: 100mL
- Viability:  $\geq 90\%$
- TNC concentration:  $\geq 8 \times 10^6$  cells/mL
- Sterility test USP <71>: No growth
- Shipping: 15 to 30°C in validated shipping container with temperature logger
- Documentation: CoA and SoR

COMING SOON


# AllCells<sup>®</sup> GMP Cryopreserved PBMCs

Overcome target cell isolation bottlenecks in CGT manufacturing workflow

## Why Choose AllCells<sup>®</sup> GMP Cryopreserved PBMCs?

- Full control of the process from GMP donor screening and leukapheresis collection to cell processing and cryopreservation
- Closed-system PBMC isolation within ISO 7 cleanroom
- Integrated donor clinic and lab minimizes time between collection, processing, and cryopreservation, maximizing cell quality
- Pre-screen off-the-shelf PBMC lots to predict downstream performance—no SOW or MSA required
- Customized solutions are available

Parameter	Off-the-Shelf	Made-to-Order
Donor meets 21 CFR 1271 criteria	✓	✓
Program-specific IDM and donor criteria	-	✓
Closed isolation system using the Sepax C-Pro	✓	✓
Meet Discovery's viability and cell concentration specifications	✓	✓
Donor HLA typed	✓	✓
Sterility and endotoxin tested	✓	✓
Available in vial format	✓	✓
Available in bag format	Inquire	✓
Ability to pre-screen PBMC lots	✓	Inquire
SOW/MSA requirement	-	✓
Certificate of Analysis, Summary of Records, Immunophenotype Report, CBC 5-Part Differential Report	✓	✓





# Serving the Full Continuum of CGT

Discovery maintains the same high quality material and stringent protocols for both research and GMP use products for a seamless transition.



	PRE-CLINICAL PHASE RESEARCH USE ONLY	CLINICAL PHASES I / II / III GMP USE	COMMERCIALIZATION
<b>Donor Assessment and Testing</b>	Donors are subject to infectious disease marker testing for HIV, Hepatitis B, and Hepatitis C. Donors also undergo a physical exam.	Donors are subject to infectious disease marker testing in compliance with 21 CFR 1271, as well as those recommended by CDC and AABB. Donors also undergo a physical exam and must pass the donor health questionnaire.	
<b>Donor Consent (IRB Approved)</b>	For research use only	For research and commercial use.	
<b>Operational SOPs</b>	Validated SOPs/e-batch records	Validated SOPs and extensive batch records.	
<b>Regulatory Compliance</b>	For research use only	Products are manufactured in accordance with FDA Title 21 Part 1271 Subparts A-C and provisions of Subpart D deemed applicable by Discovery under Section 1271.150(c) and good industry practice.	
<b>Quality</b>	E-documentation, product specifications based on process experience, certificate of analysis	QMS-governed documentation e.g. batch records, equipment and product validation, stability studies, to support product for further manipulation.	
<b>Processing Facility</b>	GMP-like collection and processing facilities	ISO 7 cleanroom with Grade A and B zones.	
<b>Packaging Protocol and Packaging</b>	Commercial grade	Packaging validated to ISTA standards including temperature logger.	

# Donor Qualification for GMP Products

We follow donor eligibility infectious disease marker testing in compliance with 21 CFR 1271, as well as the recommendations by CDC and AABB.

- Human immunodeficiency virus Type 1 antibodies and RNA
- Human immunodeficiency virus Type 2 antibodies and RNA
- Hepatitis B antibodies and DNA
- Hepatitis C antibodies and RNA
- Human T-lymphotropic Virus I/II antibodies
- Cytomegalovirus (CMV) antibodies
- West Nile virus RNA
- Trypanosoma cruzi parasite (Chagas Disease) antibodies
- Treponema pallidum (Syphilis) antibodies

Donor health questionnaire to rule out risk of Human transmissible spongiform encephalopathy, including Creutzfeldt-Jakob disease.

Discovery performs the FDA specified HCT/P donor screening  $\leq 30$  days prior to collection to assure that the donor meets inclusion criteria at the  $\leq 7$  day time point. We employ a Parallel Donor Program to mitigate the risk of donor deferrals.

Additional infectious disease marker testing and screening time points may be customized.

## **DONORS TO BE IDENTIFIED BASED ON THE STANDARD CRITERIA**

- Donors selected from the community at large in compliance with the donor eligibility criteria outlined in 21 CFR Part 1271 Subpart C - Donor Eligibility
- Gender: Male or Female
- Age: 18 to 45 years old
- Weight: 140 to 275 pounds
- No self-reported abuse of drugs or alcohol
- Not pregnant

# Donor Management Services



## Recruitment

Ongoing and client-specific donor recruitment efforts



## Screening

Standard viral screening and/or client-specific protocols



## Monitoring

Premier access to Discovery's AllCells® donor database to identify donors with study-specific attributes



## Retention

Active donor engagement to foster repeat/recallable donors; maintain minimum client-specific donor pool size

## MEETING YOUR SPECIFIC DONOR REQUIREMENTS

At Discovery, we understand that donors meeting the stringent regulatory criteria is just as critical as meeting the specific project needs for the success of the product and subsequent application.

We maintain an exclusive donor pool that is highly reliable, characterized, and qualified for the collection of GMP products. This ensures that we can deliver high-quality products on your timeline

Our proprietary AllCells® Donor Management System (DMS) enables us to optimize our processes from recruitment, screening, monitoring, and retention, ultimately empowering us to provide the right donor for every project with the shortest lead times in the market.

Our diverse, dynamic, and continuously expanding donor pool enables us to provide the match customers need to successfully complete their study.

- Healthy donors
- Recallable or unique donors
- HLA type (low and high resolution)
- KIR type
- CMV status (negative or positive)
- Blood type
- Demographics (gender, age, ethnicity)
- Specific lifestyle characteristics (BMI, smoking status, and more)
- Additional custom criteria (screening or testing)
- Dedicated donor pools

All collections are from donors who are qualified for participation in accordance with the IRB approved informed consents and meet our quality standards.

# The Right Donors for Every Project

## Premier Access to our Donor Repository

Discovery has a large, diverse donor pool, with facilities strategically located across the United States. GMP and RUO products are available at our Alameda, CA and Quincy, MA locations, enabling geographic diversity for supply chain risk mitigation. Fresh products for same day delivery are available across sites.

**DISCOVERY**  
L I F E S C I E N C E S

AllCells® Collection Facilities

**BAY AREA**

**BOSTON METRO**


- FDA-registered
- AABB-accredited (Alameda, CA)
- Experienced technical and clinical team
- Strict IRB compliance, regulatory oversight
- Donors meeting FDA 21 CFR 1271 requirements



# A Unique Donor Ecosystem

Reliability and recallability is built into the program.

- Innovative software targets specific donors to get the right donors for every project
- Collection cadence / timeline specifications
- Recruitment based on demand and forecast
- Dedicated, reserved donor pool options available



# 99% GMP Collections Deliverability

*The interplay of a robust donor ecosystem, donor characterization and deliverability of high quality starting materials helps establish robust manufacturing processes.*

With years of providing materials for GMP use and over 20 years in the CGT industry, we are your reliable and trusted supplier of high-quality starting material to support your cell therapy commercialization journey.

Our dynamic and continuously expanding donor pool and facilities provides you continuous and assured access to high-quality starting material to support scalability throughout your product lifecycle.

Our dedicated team of scientists, clinicians, quality and logistics experts will partner with you to define, design and manage your project to deliver a product that meets your specific needs.

For more information on AllCells® GMP products and services, please visit [allcells.com/gmp](https://allcells.com/gmp).



**GMP  
CLEAN ROOM  
(ALAMEDA, CALIFORNIA)**



**REGULATORY  
COMPLIANCE**



**AABB  
ACCREDITATION  
(ALAMEDA, CALIFORNIA)**



**COMPETITIVE  
PRICING**



**DISCOVERY**  
L I F E S C I E N C E S

Science at your Service™

Contact us at [info@allcells.com](mailto:info@allcells.com)  
or visit [www.allcells.com](http://www.allcells.com) to learn more  
about our AllCells® products and services.